Abstract
The COVID-19 pandemic and the associated prevention measures did not only impact on the transmission of COVID-19 but also on the spread of other infectious diseases in an unprecedented natural experiment. Here, we analysed the transmission patterns of 22 different infectious diseases during the COVID-19 pandemic in England. Our results show that the COVID-19 prevention measures generally reduced the spread of pathogens that are transmitted via the air and the faecal-oral route. Moreover, the COVID-19 prevention measures resulted in the sustained suppression of vaccine-preventable infectious diseases also after the removal of restrictions, while non-vaccine preventable diseases displayed a rapid rebound. Despite concerns that a lack of exposure to common pathogens may affect population immunity and result in large outbreaks by various pathogens post-COVID-19, only four of the 22 investigated diseases and disease groups displayed higher post-than pre-pandemic levels without an obvious causative relationship. Notably, this included chickenpox for which an effective vaccine is available but not used in the UK, which provides strong evidence supporting the inclusion of the chickenpox vaccination into the routine vaccination schedule in the UK. In conclusion, our findings provide unique, novel insights into the impact of non-pharmaceutical interventions on the spread of a broad range of infectious diseases.
Competing Interest Statement
The authors have declared no competing interest.
Funding Statement
This work was supported by the BBSRC via the SoCoBio DTP and the Frankfurter Stiftung fuer krebskranke Kinder.
Author Declarations
I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.
Yes
The details of the IRB/oversight body that provided approval or exemption for the research described are given below:
Source data were openly available before the initiation of this study from UK Health Security Agency (UKHSA) Notifications of Infectious Diseases (NOIDs) database [https://www.gov.uk/government/collections/notifications-of-infectious-diseases-noids], UKHSA/ Office for National Statistics (ONS) MRSA bacteraemia monthly count reports [https://www.gov.uk/government/statistics/mrsa-bacteraemia-monthly-data-by-location-of-onset], Royal Collage of General Practitioners (RCGP) Research and Surveillance Centre (RSC) public health data [https://www.rcgp.org.uk/representing-you/research-at-rcgp/research-surveillance-centre/public-health-data], Coronavirus (COVID-19) Infection Survey of the ONS [https://www.ons.gov.uk/peoplepopulationandcommunity/healthandsocialcare/conditionsanddiseases/datasets/coronaviruscovid19infectionsurveydata], and technical briefing 44 (22 July 2022) of UKHSA [https://www.gov.uk/government/publications/investigation-of-sars-cov-2-variants-technical-briefings].
I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.
Yes
I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).
Yes
I have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.
Yes
Data Availability
All data produced in the present work are contained in the manuscript.